Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today... | May 31, 2023

Related Keywords

Kinnari Patel ,Nasdaq ,Rocket Pharmaceuticals Inc ,European Medicines Agency ,York Heart Association ,Rocket Pharmaceuticals ,Priority Medicines ,Danon Disease ,Regenerative Medicine Advanced Therapy ,Fast Track ,Orphan Drug ,Rare Pediatric ,Chief Operating Officer ,European Regulatory ,New York Heart Association ,Kansas City Cardiomyopathy ,Fanconi Anemia ,Leukocyte Adhesion Deficiency I ,Pyruvate Kinase Deficiency ,Nc Stock Exchange ,News ,Information ,Press Release ,Rocket ,Reading ,Biotechnology ,Company ,Dvancing ,N ,Ntegrated ,End ,Ustainable ,Pipeline ,F ,Enetic ,Therapies ,Or ,Mare ,Disorders ,Ith ,Thigh ,Nmet Rckt Us77313f1066 ,